Mustang Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.4M
- Price
- $0.5787
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.01%
- Volume
- 6.5K
About
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Quick stats
Shares outstanding7.6M
Computed float6.2M
Float / shares81.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001680048
Websitehttps://www.mustangbio.com
AI Summary
AI-generated1/9
minorbullishproduct launch
MindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection Kiosks
MindBio Therapeutics has completed the manufacture and delivery of its first prototype Edge AI Intoxication and Fatigue Detection Kiosks.
The hardware and software solution uses voice analysis powered by AI to detect intoxication and fatigue, targeting high-risk industries such as mining, aviation, and construction.
The prototypes will now undergo rigorous testing, model validation, and data analysis in consultation with industry experts before any commercial rollout.
Red flags
- Pre-revenue company relying on forward-looking statements for commercial viability
- Risk factors cite potential failure to raise capital and obtain regulatory approval